Effect of MitoQ on Platelet Function and Reactive Oxygen Species Generation in Patients With Sickle Cell Anemia

Recruiting now · Not applicable

Conditions studied: Sickle Cell Disease

In brief

MitoQ is commercially available as a dietary supplement and it has been tested as a potential drug in other diseases, but it has never been tested in patients with sickle cell disease. The goal of this research is to study if MitoQ, a molecule that works as an antioxidant by removing potentially damaging agents in a living organism, improves platelet function in patients with sickle cell disease (SCD).

Key facts

Study ID

NCT04109820

Run by

University of Pittsburgh

People needed

15

Starts

2020-03-01

Expected to finish

2027-06-30

Last updated by the study team

2025-06-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Subjects
• African American
• Patients with sickle cell anemia
• 18 years old or older
• Control
• African American healthy controls
• 18 years of age or older

You may not qualify if…

• Pregnancy,
• Known hypertension,
• Hemodialysis and active obstructive sleep apnea requiring treatment.
• Use of anti-platelet medication or have had transfusion in the 4 weeks prior to enrollment.

Where it is running

• Magee Women's Hospital — Pittsburgh, Pennsylvania, United States (enrolling)
• UPMC Montefiore — Pittsburgh, Pennsylvania, United States (enrolling)
• UPMC Presbyterian — Pittsburgh, Pennsylvania, United States (enrolling)
• Children's Hospital of Pittsburgh — Pittsburgh, Pennsylvania, United States (enrolling)
• Hillman Cancer Center — Pittsburgh, Pennsylvania, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.